TY -的T1 Neurofilament-Light链水平预测持续的疾病活动的影像上孤立综合症(S37.003) JF -神经学乔-神经学六世- 92 - 15补充Eric Thouvenot SP - S37.003盟盟-克利斯朵夫Demattei盟Ugur Uygunoglu A首页U -苏菲Pittion盟Giovanni Castelnovo盟Luciel Du Trieu de Terdonck AU -米凯尔·科恩盟达林奥田硕AU - Orhun Kantarci AU -丹尼尔·佩尔蒂埃盟-菲利普·马林盟Sylvain莱曼AU -湿婆Aksel盟Christine Lebrun Frenay Y1 - 2019/04/09 UR - //www.ez-admanager.com/content/92/15_Supplement/S37.003.abstract N2 -目的:评估Neurofilament-Light链(sNfL)的预测价值的危险疾病活动的证据(EDA)和临床转换(CC)的放射检查孤立综合症患者(RIS)。背景:EDA(新MRI病灶和/或临床事件)是多发性硬化症(MS)的特征,与复发的风险增加有关。除了年轻,男性和脊髓病变(s),高架脑脊液(CSF) NfL和存在免疫球蛋白G寡克隆乐队(时常)最近被确定为预测的CC RIS科目。设计/方法:我们测量sNfL和CSF NfL水平由单分子阵列(RIS Simoa Quanterix)患者2009 RIS所定义的标准。我们分析的影响,年龄、性别、2005传播空间(DIS)标准,脊髓损伤,gadolinium-enhanced病变,台籍干部,sNfL和CSF NfL EDA和CC使用kaplan meier的风险分析和Cox回归模型。结果:62年RIS患者包括从4女士中心。平均随访时间是45个月。CSF NfL在包容和sNfL水平高度相关(枪兵,r = 0.783)。Kaplan-Meier analysis revealed that presence of OCB, CSF NfL>400pg/mL, sNfL>6.5pg/mL and presence of 4/4 2005 DIS criteria were predictive of disease activity (log rank, p=0.017, p=0.022, p=0.025 and p=0.45, respectively). Especially, patients with 4/4 2005 DIS criteria and/or sNfL>6.5pg/mL had an 86% risk of EDA compared to 54% without these characteristics. Only CSF NfL levels predicted CC during follow-up (log rank, p=0.033). Multivariate Cox regression model revealed that OCB, MRI criteria and sNfL>6.5pg/mL were independent factors of EDA (HR=1.87, p=0.047; HR=2.21, p=0.025 and HR=2.19, p=0.019, respectively), but not of CC.Conclusions: Elevated sNfL, OCB and 2005 MRI criteria are predictive of EDA in RIS. If replicated in larger datasets, these biomarkers may inform on treatment decisions in this highly relevant population.On behalf of RISC and SFSEP.Disclosure: Dr. Thouvenot has nothing to disclose. Dr. Demattei has nothing to disclose. Dr. Uygunoglu has nothing to disclose. Dr. Pittion has nothing to disclose. Dr. Castelnovo has nothing to disclose. Dr. Du Trieu de Terdonck has nothing to disclose. Dr. Cohen has nothing to disclose. Dr. Okuda has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with received advisory and consulting fees from Celgene, EMD Serono, Genentech, Genzyme, and Novartis. Dr. Okuda has received research support from Biogen. Dr. Kantarci has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Novartis Pharmaceuticals and Biogen. Dr. Kantarci has received research support from Biogen, the Multiple Sclerosis Society, the Mayo Foundation, and the Hilton Foundation. Dr. Pelletier has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Biogen, Merck Serono, Novartis, Roche, and Sanofi. Dr. Pelletier has received research support from Biogen, Merck Serono, Novartis, Roche, and Sanofi. Dr. Marin has nothing to disclose. Dr. Lehmann has nothing to disclose. Dr. Siva has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Merck, Novarti Pharmaceuticals, Teva, Sanofi Genzyme, Bayer, and Roche. Dr. Lebrun Frenay has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Bayer Schering, Biogen, Genzyme, Merck Serono, Novartis Pharmaceuticals, and Teva. ER -